Citations (78)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Kriti Kashyap & Rita Kakkar. (2021) Exploring structural requirements of isoform selective histone deacetylase inhibitors: a comparative in silico study. Journal of Biomolecular Structure and Dynamics 39:2, pages 502-517.
Read now
Read now
Nuggehally R. Srinivas. (2017) Clinical pharmacokinetics of panobinostat, a novel histone deacetylase (HDAC) inhibitor: review and perspectives. Xenobiotica 47:4, pages 354-368.
Read now
Read now
Fortunato Morabito, Maria Teresa Voso, Stefan Hohaus, Massimo Gentile, Ernesto Vigna, Anna Grazia Recchia, Lorenzo Iovino, Edoardo Benedetti, Francesco Lo-Coco & Sara Galimberti. (2016) Panobinostat for the treatment of acute myelogenous leukemia. Expert Opinion on Investigational Drugs 25:9, pages 1117-1131.
Read now
Read now
Suzanne F. Jones, Jeffrey R. Infante, David R. Spigel, Nancy W. Peacock, Dana S. Thompson, F. Anthony Greco, William McCulloch & Howard A. Burris III. (2012) Phase 1 Results From a Study of Romidepsin in Combination With Gemcitabine in Patients With Advanced Solid Tumors. Cancer Investigation 30:6, pages 481-486.
Read now
Read now
Edwin F. de Zoeten, Liqing Wang, Kyle Butler, Ulf H. Beier, Tatiana Akimova, Hong Sai, James E. Bradner, Ralph Mazitschek, Alan P. Kozikowski, Patrick Matthias & Wayne W. Hancock. (2011) Histone Deacetylase 6 and Heat Shock Protein 90 Control the Functions of Foxp3+ T-Regulatory Cells. Molecular and Cellular Biology 31:10, pages 2066-2078.
Read now
Read now
Rebecca A Howman & H Miles Prince. (2011) New drug therapies in peripheral T-cell lymphoma. Expert Review of Anticancer Therapy 11:3, pages 457-472.
Read now
Read now
Joslyn S Kirby, Ellen J Kim & Alain H Rook. (2009) Therapy of Sézary syndrome. Expert Review of Dermatology 4:6, pages 567-579.
Read now
Read now
Articles from other publishers (71)
M. А. Sorokina, A. V. Rakhteenko & T. R. Grishina. (2023) New pharmacotherapeutic approaches for the treatment of peripheral T-cell lymphoma. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 16:2, pages 291-302.
Crossref
Crossref
Rafia Akhlaq, Tajwali Khan, Tehmina Ahmed, Syed G. Musharraf & Arslan Ali. (2023) PX‐12 synergistically enhances the therapeutic efficacy of vorinostat under hypoxic tumor microenvironment in oral squamous cell carcinoma in vitro. Drug Development Research 84:3, pages 606-610.
Crossref
Crossref
Lina Hu, Xuanye Zhang, Huifeng Li, Suxia Lin & Shengbing Zang. (2022) Targeting TET2 as a Therapeutic Approach for Angioimmunoblastic T Cell Lymphoma. Cancers 14:22, pages 5699.
Crossref
Crossref
Changjun Wang, Yan Lin, Hanjiang Zhu, Yidong Zhou, Feng Mao, Xin Huang, Qiang Sun & Chenggang Li. (2022) Efficacy and Safety Profile of Histone Deacetylase Inhibitors for Metastatic Breast Cancer: A Meta-Analysis. Frontiers in Oncology 12.
Crossref
Crossref
Alain Mina & Barbara Pro. (2022) T time: Emerging and new therapies for peripheral T-cell lymphoma. Blood Reviews 52, pages 100889.
Crossref
Crossref
Skye Hsin-Hsien Yeh, Ming Hsien Lin, I. I. Leo Garcia Flores, Uday Mukhopadhyay, Danial Young, Kazuma Ogawa, Jeong-Hwan Jeong, William Tong, Juri G. Gelovani & Nobuyoshi Fukumitsu. (2021) In Vivo Evaluation of the Combined Anticancer Effects of Cisplatin and SAHA in Nonsmall Cell Lung Carcinoma Using [18F]FAHA and [18F]FDG PET/CT Imaging. Molecular Imaging 2021, pages 1-11.
Crossref
Crossref
Maria Mrakovcic & Leopold F. Fröhlich. 2019. Genes and Cancer. Genes and Cancer.
Zefei Jiang, Wei Li, Xichun Hu, Qingyuan Zhang, Tao Sun, Shude Cui, Shusen Wang, Quchang Ouyang, Yongmei Yin, Cuizhi Geng, Zhongsheng Tong, Ying Cheng, Yueyin Pan, Yuping Sun, Hong Wang, Tao Ouyang, Kangsheng Gu, Jifeng Feng, Xiaojia Wang, Shubin Wang, Tianshu Liu, Jinghua Gao, Massimo Cristofanilli, Zhiqiang Ning & Xianping Lu. (2019) Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet Oncology 20:6, pages 806-815.
Crossref
Crossref
Maria Mrakovcic, Johannes Kleinheinz & Leopold F. Fröhlich. (2019) p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death. International Journal of Molecular Sciences 20:10, pages 2415.
Crossref
Crossref
Maria Mrakovcic, Lauren Bohner, Marcel Hanisch & Leopold F. Fröhlich. (2018) Epigenetic Targeting of Autophagy via HDAC Inhibition in Tumor Cells: Role of p53. International Journal of Molecular Sciences 19:12, pages 3952.
Crossref
Crossref
Chen Ai & Lei Kong. (2018) CGPS: A machine learning-based approach integrating multiple gene set analysis tools for better prioritization of biologically relevant pathways. Journal of Genetics and Genomics 45:9, pages 489-504.
Crossref
Crossref
Shabir Ahmad Ganai, Zeenat Farooq, Shahid Banday & Mohammad Altaf. (2018)
In silico
approaches for investigating the binding propensity of apigenin and luteolin against class I HDAC isoforms
. Future Medicinal Chemistry 10:16, pages 1925-1945.
Crossref
Crossref
Dong Hoon Lee, Hyun-Wook Ryu, Hye-Rim Won & So Hee Kwon. (2017) Advances in epigenetic glioblastoma therapy. Oncotarget 8:11, pages 18577-18589.
Crossref
Crossref
Vincent Pillonel, Nina Reichert, Chun Cao, Marinus R. Heideman, Teppei Yamaguchi, Gabriele Matthias, Alexandar Tzankov & Patrick Matthias. (2016) Histone deacetylase 1 plays a predominant pro-oncogenic role in Eμ-myc driven B cell lymphoma. Scientific Reports 6:1.
Crossref
Crossref
Wayne W. Hancock. (2016) Isoform-Selective HDAC Inhibitor Therapy for Transplantation. Transplantation 100:8, pages 1597-1598.
Crossref
Crossref
Clémence Basse & Michel Arock. (2014) The increasing roles of epigenetics in breast cancer: Implications for pathogenicity, biomarkers, prevention and treatment. International Journal of Cancer 137:12, pages 2785-2794.
Crossref
Crossref
Geoffrey M. MatthewsParinaz MehdipourLeonie A. CluseKatrina J. FalkenbergEric WangMareike RothFabio SantoroEva VidacsKym StanleyColin M. HouseJames R. RuscheChristopher R. VakocJohannes ZuberSaverio Minucci & Ricky W. Johnstone. (2015) Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies. Blood 126:21, pages 2392-2403.
Crossref
Crossref
Shabir Ahmad Ganai. (2015) Strategy for enhancing the therapeutic efficacy of histone deacetylase inhibitor dacinostat: the novel paradigm to tackle monotonous cancer chemoresistance. Archives of Pharmacal Research.
Crossref
Crossref
Claudia V. Andreu-Vieyra & James R. Berenson. (2014) The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. Therapeutic Advances in Hematology 5:6, pages 197-210.
Crossref
Crossref
Marije Slingerland, Dagmar Hess, Sally Clive, Sunil Sharma, Per Sandstrom, Niklas Loman, Maria G. Porro, Song Mu, Edward Waldron, Sue-zette Valera & Hans Gelderblom. (2014) A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and various degrees of hepatic function. Cancer Chemotherapy and Pharmacology 74:5, pages 1089-1098.
Crossref
Crossref
S L Locatelli, L Cleris, G G Stirparo, S Tartari, E Saba, M Pierdominici, W Malorni, A Carbone, A Anichini & C Carlo-Stella. (2014) BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts. Leukemia 28:9, pages 1861-1871.
Crossref
Crossref
Christian Marinaccio, Beatrice Nico, Eugenio Maiorano, Giorgina Specchia & Domenico Ribatti. (2014) Insights in Hodgkin Lymphoma angiogenesis. Leukemia Research 38:8, pages 857-861.
Crossref
Crossref
Simon G. Royce, Yuben Moodley & Chrishan S. Samuel. (2014) Novel therapeutic strategies for lung disorders associated with airway remodelling and fibrosis. Pharmacology & Therapeutics 141:3, pages 250-260.
Crossref
Crossref
Mehdi Hamadani, Sarah M. Abu Kar, Saad Z. Usmani, Bipin N. Savani, Ernesto Ayala & Mohamed A. Kharfan-Dabaja. (2014) Management of Relapses After Hematopoietic Cell Transplantation in T-Cell Non-Hodgkin Lymphomas. Seminars in Hematology 51:1, pages 73-86.
Crossref
Crossref
Jane Jisun Sung & Tom C. Karagiannis. 2014. Molecular mechanisms and physiology of disease. Molecular mechanisms and physiology of disease
445
470
.
Andrea Newbold, Geoffrey M. Matthews, Michael Bots, Leonie A. Cluse, Christopher J.P. Clarke, Kellie-Marie Banks, Carleen Cullinane, Jessica E. Bolden, Ailsa J. Christiansen, Ross A. Dickins, Claudia Miccolo, Susanna Chiocca, Astrid M. Kral, Nicole D. Ozerova, Thomas A. Miller, Joey L. Methot, Victoria M. Richon, J. Paul Secrist, Saverio Minucci & Ricky W. Johnstone. (2013) Molecular and Biologic Analysis of Histone Deacetylase Inhibitors with Diverse Specificities. Molecular Cancer Therapeutics 12:12, pages 2709-2721.
Crossref
Crossref
G M Matthews, M Lefebure, M A Doyle, J Shortt, J Ellul, M Chesi, K-M Banks, E Vidacs, D Faulkner, P Atadja, P L Bergsagel & R W Johnstone. (2013) Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma. Cell Death & Disease 4:9, pages e798-e798.
Crossref
Crossref
Koppany Visnyei, Michael L. Grossbard & Ilan Shapira. (2013) Hepatosplenic γδ T-cell Lymphoma: An Overview. Clinical Lymphoma Myeloma and Leukemia 13:4, pages 360-369.
Crossref
Crossref
Angie L. McGraw. (2013) Romidepsin for the treatment of T-cell lymphomas. American Journal of Health-System Pharmacy 70:13, pages 1115-1122.
Crossref
Crossref
Stacey M. Frumm, Zi Peng Fan, Kenneth N. Ross, Jeremy R. Duvall, Supriya Gupta, Lynn VerPlank, Byung-Chul Suh, Edward Holson, Florence F. Wagner, William B. Smith, Ronald M. Paranal, Christopher F. Bassil, Jun Qi, Giovanni Roti, Andrew L. Kung, James E. Bradner, Nicola Tolliday & Kimberly Stegmaier. (2013) Selective HDAC1/HDAC2 Inhibitors Induce Neuroblastoma Differentiation. Chemistry & Biology 20:5, pages 713-725.
Crossref
Crossref
Domenico Ribatti, Beatrice Nico, Girolamo Ranieri, Giorgina Specchia & Angelo Vacca. (2013) The Role of Angiogenesis in Human Non-Hodgkin Lymphomas. Neoplasia 15:3, pages 231-238.
Crossref
Crossref
J E Bolden, W Shi, K Jankowski, C-Y Kan, L Cluse, B P Martin, K L MacKenzie, G K Smyth & R W Johnstone. (2013) HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death & Disease 4:2, pages e519-e519.
Crossref
Crossref
M. S. I. Abaza, A. M. Bahman, R. J. Al-Attiyah & A. M. Kollamparambil. (2012) Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome inhibitors: potential mechanisms of action. Tumor Biology 33:6, pages 1951-1972.
Crossref
Crossref
Viktor Brabec, Darren M. Griffith, Anna Kisova, Hana Kostrhunova, Lenka Zerzankova, Celine J. Marmion & Jana Kasparkova. (2012)
Valuable Insight into the Anticancer Activity of the Platinum-Histone Deacetylase Inhibitor Conjugate,
cis
-[Pt(NH
3
)
2
malSAHA
–2H
)]
. Molecular Pharmaceutics 9:7, pages 1990-1999.
Crossref
Crossref
Mei Dong, Zhi-Qiang Ning, Pu-Yuan Xing, Jia-Lian Xu, Hai-Xiang Cao, Gui-Fang Dou, Zhi-Yun Meng, Yuan-Kai Shi, Xian-Ping Lu & Feng-Yi Feng. (2012) Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas. Cancer Chemotherapy and Pharmacology 69:6, pages 1413-1422.
Crossref
Crossref
Bertrand CoiffierBarbara ProH. Miles PrinceFrancine FossLubomir SokolMatthew GreenwoodDolores CaballeroPeter BorchmannFranck MorschhauserMartin WilhelmLauren Pinter-BrownSwaminathan PadmanabhanAndrei ShustovJean NicholsSusan CarrollJohn BalserBarbara BalserSteven Horwitz. (2012) Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy. Journal of Clinical Oncology 30:6, pages 631-636.
Crossref
Crossref
Katherine A. Lyseng-Williamson & Lily P.H. Yang. (2012) Romidepsin: A Guide to its Clinical Use in Cutaneous T-Cell Lymphoma. American Journal of Clinical Dermatology 13:1, pages 67-71.
Crossref
Crossref
Robert W. Robey, Arup R. Chakraborty, Agnes Basseville, Victoria Luchenko, Julian Bahr, Zhirong Zhan & Susan E. Bates. (2011) Histone Deacetylase Inhibitors: Emerging Mechanisms of Resistance. Molecular Pharmaceutics 8:6, pages 2021-2031.
Crossref
Crossref
Jacob E. Shabason, Philip J. Tofilon & Kevin Camphausen. (2011) Grand rounds at the National Institutes of Health: HDAC inhibitors as radiation modifiers, from bench to clinic. Journal of Cellular and Molecular Medicine 15:12, pages 2735-2744.
Crossref
Crossref
Katherine Ververis, Annabelle L. Rodd, Michelle M. Tang, Assam El-Osta & Tom C. Karagiannis. (2011) Histone deacetylase inhibitors augment doxorubicin-induced DNA damage in cardiomyocytes. Cellular and Molecular Life Sciences 68:24, pages 4101-4114.
Crossref
Crossref
Ádám Jóna, Noor Khaskhely, Daniela Buglio, Jessica A. Shafer, Enrico Derenzini, Catherine M. Bollard, L. Jeffrey Medeiros, Árpád Illés, Yuan Ji & Anas Younes. (2011) The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Experimental Hematology 39:10, pages 1007-1017.e1.
Crossref
Crossref
Lauren Martz. (2011) Giving Treg cells a boost. Science-Business eXchange 4:21.
Crossref
Crossref
Adrian P. Wiegmans, Amber E. Alsop, Michael Bots, Leonie A. Cluse, Steven P. Williams, Kellie-Marie Banks, Rachael Ralli, Clare L. Scott, Anna Frenzel, Andreas Villunger & Ricky W. Johnstone. (2011) Deciphering the Molecular Events Necessary for Synergistic Tumor Cell Apoptosis Mediated by the Histone Deacetylase Inhibitor Vorinostat and the BH3 Mimetic ABT-737. Cancer Research 71:10, pages 3603-3615.
Crossref
Crossref
Daruka MahadevanRichard I. Fisher. (2011) Novel Therapeutics for Aggressive Non-Hodgkin's Lymphoma. Journal of Clinical Oncology 29:14, pages 1876-1884.
Crossref
Crossref
Benjamin Briggs, Katherine Ververis, Annabelle L. Rodd, Laura J.L. Foong, Fernando M. Da Silva & Tom C. Karagiannis. (2011) Photosensitization by iodinated DNA minor groove binding ligands: Evaluation of DNA double-strand break induction and repair. Journal of Photochemistry and Photobiology B: Biology 103:2, pages 145-152.
Crossref
Crossref
Mario Varasi, Florian Thaler, Agnese Abate, Chiara Bigogno, Roberto Boggio, Giacomo Carenzi, Tiziana Cataudella, Roberto Dal Zuffo, Maria Carmela Fulco, Marco Giulio Rozio, Antonello Mai, Giulio Dondio, Saverio Minucci & Ciro Mercurio. (2011) Discovery, Synthesis, and Pharmacological Evaluation of Spiropiperidine Hydroxamic Acid Based Derivatives as Structurally Novel Histone Deacetylase (HDAC) Inhibitors. Journal of Medicinal Chemistry 54:8, pages 3051-3064.
Crossref
Crossref
H Hasegawa, Y Yamada, K Tsukasaki, N Mori, K Tsuruda, D Sasaki, T Usui, A Osaka, S Atogami, C Ishikawa, Y Machijima, S Sawada, T Hayashi, Y Miyazaki & S Kamihira. (2011) LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway. Leukemia 25:4, pages 575-587.
Crossref
Crossref
Ailsa J. Christiansen, Alison West, Kellie-Marie Banks, Nicole M. Haynes, Michele W. Teng, Mark J. Smyth & Ricky W. Johnstone. (2011) Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proceedings of the National Academy of Sciences 108:10, pages 4141-4146.
Crossref
Crossref
Shambhunath Choudhary, Kwo‐Kwang Abraham Wang & Hwa‐Chain Robert Wang. (2010)
Oncogenic H‐Ras, FK228, and exogenous H
2
O
2
cooperatively activated the erk pathway in selective induction of human urinary bladder cancer j82 cell death
. Molecular Carcinogenesis 50:3, pages 215-219.
Crossref
Crossref
C R Giver, D L Jaye, E K Waller, J L Kaufman & S Lonial. (2010) Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes. Leukemia 25:2, pages 362-365.
Crossref
Crossref
Takashi Murakami. 2011. Experimental and Applied Immunotherapy. Experimental and Applied Immunotherapy
307
322
.
Sean J. WhittakerMarie-France DemierreEllen J. KimAlain H. RookAdam LernerMadeleine DuvicJulia ScarisbrickSunil ReddyTadeusz RobakJürgen C. BeckerAlexey SamtsovWilliam McCullochYoun H. Kim. (2010) Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma. Journal of Clinical Oncology 28:29, pages 4485-4491.
Crossref
Crossref
Theresa K Kelly, Daniel D De Carvalho & Peter A Jones. (2010) Epigenetic modifications as therapeutic targets. Nature Biotechnology 28:10, pages 1069-1078.
Crossref
Crossref
Tom C Karagiannis, Ann JE Lin, Katherine Ververis, Lisa Chang, Michelle M Tang, Jun Okabe & Assam El-Osta. (2010) Trichostatin A accentuates doxorubicin-induced hypertrophy in cardiac myocytes. Aging 2:10, pages 659-668.
Crossref
Crossref
Roel H Wilting, Eva Yanover, Marinus R Heideman, Heinz Jacobs, James Horner, Jaco van der Torre, Ronald A DePinho & Jan-Hermen Dannenberg. (2010) Overlapping functions of Hdac1 and Hdac2 in cell cycle regulation and haematopoiesis. The EMBO Journal 29:15, pages 2586-2597.
Crossref
Crossref
Dana Rathkopf, Bryan Y. Wong, Robert W. Ross, Aseem Anand, Erika Tanaka, Margaret M. Woo, Jing Hu, Andy Dzik-Jurasz, Wei Yang & Howard I. Scher. (2010) A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology 66:1, pages 181-189.
Crossref
Crossref
Jacqueline RamírezMark J RatainFederico Innocenti. (2010) Uridine 5´-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncology 6:4, pages 563-585.
Crossref
Crossref
A Villagra, E M Sotomayor & E Seto. (2009) Histone deacetylases and the immunological network: implications in cancer and inflammation. Oncogene 29:2, pages 157-173.
Crossref
Crossref
Noriyasu Fukushima & Shinya Kimura. (2010) Current and future issue of molecular target therapy in hematological malignancy. Drug Delivery System 25:2, pages 126-133.
Crossref
Crossref
Keeran Sampat, Adriana Rossi, Valentin Garcia-Gutierrez, Jorge Cortes, Sherry Pierce, Hagop Kantarjian & Guillermo Garcia-Manero. (2010) Characteristics of pericardial effusions in patients with leukemia. Cancer, pages NA-NA.
Crossref
Crossref
Liqing Wang, Edwin F. de Zoeten, Mark I. Greene & Wayne W. Hancock. (2009) Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nature Reviews Drug Discovery 8:12, pages 969-981.
Crossref
Crossref
Andrew A. LaneBruce A. Chabner. (2009) Histone Deacetylase Inhibitors in Cancer Therapy. Journal of Clinical Oncology 27:32, pages 5459-5468.
Crossref
Crossref
Yutaka Fujiwara, Noboru Yamamoto, Yasuhide Yamada, Kazuhiko Yamada, Tetsuya Otsuki, Shinichi Kanazu, Takashi Iwasa, James S. Hardwick & Tomohide Tamura. (2009) Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors. Cancer Science 100:9, pages 1728-1734.
Crossref
Crossref
John Gerecitano. (2009) The future of small molecule inhibitors in lymphoma. Current Oncology Reports 11:5, pages 378-385.
Crossref
Crossref
Oronza Antonietta Botrugno, Fabio Santoro & Saverio Minucci. (2009) Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Letters 280:2, pages 134-144.
Crossref
Crossref
Olaf Kinzel, Laura Llauger-Bufi, Giovanna Pescatore, Michael Rowley, Carsten Schultz-Fademrecht, Edith Monteagudo, Massimiliano Fonsi, Odalys Gonzalez Paz, Fabrizio Fiore, Christian Steinkühler & Philip Jones. (2009) Discovery of a Potent Class I Selective Ketone Histone Deacetylase Inhibitor with Antitumor Activity in Vivo and Optimized Pharmacokinetic Properties. Journal of Medicinal Chemistry 52:11, pages 3453-3456.
Crossref
Crossref
Renee M. Balliet, Gang Chen, Carla J. Gallagher, Ryan W. Dellinger, Dongxiao Sun & Philip Lazarus. (2009) Characterization of UGTs Active against SAHA and Association between SAHA Glucuronidation Activity Phenotype with UGT Genotype. Cancer Research 69:7, pages 2981-2989.
Crossref
Crossref
Grégory Eot-Houllier, Géraldine Fulcrand, Laura Magnaghi-Jaulin & Christian Jaulin. (2009) Histone deacetylase inhibitors and genomic instability. Cancer Letters 274:2, pages 169-176.
Crossref
Crossref
A Rocca, S Minucci, G Tosti, D Croci, F Contegno, M Ballarini, F Nolè, E Munzone, A Salmaggi, A Goldhirsch, P G Pelicci & A Testori. (2009) A phase I–II study of the histone deacetylase inhibitor valproic acid plus chemoimmunotherapy in patients with advanced melanoma. British Journal of Cancer 100:1, pages 28-36.
Crossref
Crossref
Min-Jung Lee, Yeong Sang Kim, Shivaani Kummar, Giuseppe Giaccone & Jane B Trepel. (2008) Histone deacetylase inhibitors in cancer therapy. Current Opinion in Oncology 20:6, pages 639-649.
Crossref
Crossref
Regina Fink-Puches & Lorenzo Cerroni. (2008) Cutaneous T-cell lymphoma and emerging therapies. Drug Discovery Today: Disease Mechanisms 5:1, pages e69-e79.
Crossref
Crossref